Larvol Delta - Avadel-Pharmaceuticals-Announces-First-Patient-Dosed-in-OpenLabel-ExtensionSwitch-Study-of-Investigational-OnceNightly-FT218-as-a-Potential-Treatment-for-Excessive-Daytime-Sleepiness-and-Cataplexy-in-Patients-with-Narcolepsy

sodium oxybate ER (FT218) - Avadel

https://www.globenewswire.com/news-release/2020/07/13/2061186/0/en/Avadel-Pharmaceuticals-Announces-First-Patient-Dosed-in-Open-Label-Extension-Switch-Study-of-Investigational-Once-Nightly-FT218-as-a-Potential-Treatment-for-Excessive-Daytime-Sleep.html

Jul 13, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next